Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Severe Congenital Neutropenia Due to G6PC3 Deficiency
NCT05078879Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2021
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of empagliflozin in severe congenital neutropenia (SCN), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Absolute Neutrophil Count at 12 months and Safety at 12 months. Started Nov 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
severe congenital neutropenia (SCN)
Beyond the preview
Go deeper on NCT05078879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05078879.